- Home
- WHWK vs NTRB Comparison
WHWK vs NTRB Comparison
Compare WHWK & NTRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WHWK
- NTRB
- Stock Information
- Founded
- WHWK 2007
- NTRB 2016
- Country
- WHWK United States
- NTRB United States
- Employees
- WHWK N/A
- NTRB N/A
- Industry
- WHWK Biotechnology: Pharmaceutical Preparations
- NTRB Industrial Specialties
- Sector
- WHWK Health Care
- NTRB Health Care
- Exchange
- WHWK Nasdaq
- NTRB Nasdaq
- Market Cap
- WHWK 82.4M
- NTRB 71.8M
- IPO Year
- WHWK N/A
- NTRB N/A
- Fundamental
- Price
- WHWK $1.95
- NTRB $7.15
- Analyst Decision
- WHWK
- NTRB Buy
- Analyst Count
- WHWK 0
- NTRB 1
- Target Price
- WHWK N/A
- NTRB $13.00
- AVG Volume (30 Days)
- WHWK 122.3K
- NTRB 32.3K
- Earning Date
- WHWK 11-15-2025
- NTRB 09-09-2025
- Dividend Yield
- WHWK N/A
- NTRB N/A
- EPS Growth
- WHWK N/A
- NTRB N/A
- EPS
- WHWK N/A
- NTRB N/A
- Revenue
- WHWK $21,596,000.00
- NTRB $2,578,059.00
- Revenue This Year
- WHWK N/A
- NTRB $560.75
- Revenue Next Year
- WHWK N/A
- NTRB $588.39
- P/E Ratio
- WHWK N/A
- NTRB N/A
- Revenue Growth
- WHWK N/A
- NTRB 42.92
- 52 Week Low
- WHWK $1.39
- NTRB $2.98
- 52 Week High
- WHWK $3.81
- NTRB $9.42
- Technical
- Relative Strength Index (RSI)
- WHWK 53.17
- NTRB 57.39
- Support Level
- WHWK N/A
- NTRB $5.85
- Resistance Level
- WHWK $2.04
- NTRB $7.48
- Average True Range (ATR)
- WHWK 0.09
- NTRB 0.45
- MACD
- WHWK -0.05
- NTRB 0.14
- Stochastic Oscillator
- WHWK 95.59
- NTRB 80.26
About WHWK Whitehawk Therapeutics Inc. Common Stock
Whitehawk Therapeutics Inc is a preclinical stage oncology therapeutics. The company is engaged in applying technologies to established tumor biology to efficiently deliver improved cancer treatments. The company's three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers.
About NTRB Nutriband Inc.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.